AIDS:Open market or triumvirate; DiscoverEase: From trap to model

AIDS: Open market or triumvirate?

Triple combination therapy with a protease inhibitor, Glaxo-Wellcome's AZT zidovudine and BioChem Pharma Inc.'s Epivir 3TC has quickly become the standard of care for AIDS patients. The question for a growing group of new therapies is how they will find a place in the market in addition to this triumvirate...